CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sep 6, 2018--Rheos Medicines, a biopharmaceutical company developing novel medicines that modulate metabolic pathways in immune cells to treat disease, today announced the appointment of Sanjay Keswani as Chief Executive Officer. Dr. Keswani is appointed CEO at a time when Rheos is translating new understanding of immune cell metabolism, including insights from the company’s product engine, to develop a pipeline of medicines for immune-mediated diseases and cancers. Dr. Keswani succeeds interim Chief Executive Officer and Partner at Third Rock Ventures, Abbie Celniker, PhD, who will remain on Rheos Medicine’s board of directors as Chairwoman.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180906005167/en/

Rheos CEO Sanjay Keswani (Photo: Business Wire)

“Sanjay’s broad drug development experience across multiple therapeutic areas and strong track record for building high performing teams is an ideal fit for Rheos at this time when the productivity of the company’s product engine ramps up to generate initial drug programs as well as a range of therapeutic opportunities to address many immune-mediated diseases through novel targets and concurrent biomarker approach,” said Abbie Celniker, Ph.D.

“I am excited to join the world-class team at Rheos Medicines and be a part of the pioneering effort to translate the company’s leading-edge insights and product engine in immunometabolism into novel treatments for a broad range of patients with immune-mediated diseases and cancer,” said Sanjay Keswani. “There is an immense opportunity to change the therapeutic paradigm for treating diseases that involve the immune system, and Rheos is ideally positioned to set a new standard by targeting the underlying cellular metabolism of immune cells to treat a wide range of diseases.”

Sanjay Keswani joins Rheos from Roche where he was Senior Vice President and Global Head of Neuroscience, Ophthalmology and Rare diseases for Roche Pharma Research and Early Development. Prior to Roche, he was Vice President, Exploratory and Clinical Translational Research at Bristol-Myers Squibb, where he was responsible for multiple therapeutic areas including Immunology, Neuroscience, Rare Diseases, Fibrosis and Virology. He held R&D leadership roles at Eli Lily & Co. and Amgen, Inc. and also served as Assistant Professor in Neurology at The Johns Hopkins University. Dr. Keswani completed his medical residency in Neurology and fellowships in Neuroimmunology and Neurophysiology at The Johns Hopkins University School of Medicine and his MBBS in medicine at St. Bartholomew’s Hospital, London. In addition, Dr. Keswani holds a first class honors degree from St. Mary’s Hospital, London in Pathology & Basic Medical Sciences (Immunology) and was recently elected as a Fellow of the Royal College of Physicians (FRCP).

About Rheos Medicines Rheos Medicines is a biopharmaceutical company developing novel medicines that modulate metabolic pathways in immune cells to treat disease. Our approach targets the underlying cellular metabolism of immune cells to redirect the fate and function of specific cell types to treat immune-mediated disease. By simultaneously identifying new drug targets and characterizing biomarkers of disease we are bringing precision to the treatment of immune-mediated diseases. We have brought together leading scientists whose discoveries opened the field of immunometabolism, clinicians with a deep understanding of immune-mediated diseases, and an experienced biotech leadership team. Rheos was founded by Third Rock Ventures and is located in Cambridge, MA. For more information, please visit  www.rheosrx.com.

View source version on businesswire.com:https://www.businesswire.com/news/home/20180906005167/en/

CONTACT: The Yates Network

Kathryn Morris, 914-204-6412

kathryn@theyatesnetwork.com

KEYWORD: UNITED STATES NORTH AMERICA MASSACHUSETTS

INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY INFECTIOUS DISEASES PHARMACEUTICAL GENERAL HEALTH

SOURCE: Rheos Medicines

Copyright Business Wire 2018.

PUB: 09/06/2018 07:00 AM/DISC: 09/06/2018 07:01 AM

http://www.businesswire.com/news/home/20180906005167/en